Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: J Intern Med. 2018 May 23;284(3):292–306. doi: 10.1111/joim.12767

Fig. 4.

Fig. 4

VitD3 analysis. Plasma levels of 25(OH)D3 in the placebo compared to the vitD3+PBA group at baseline and at weeks 4, 8, and 16 after initiation of anti-TB chemotherapy. Data are shown in a scatter dot plot with blue symbols for placebo and red symbols for vitD3+PBA treatment. The solid line indicates the median, and the dashed lines mark the thresholds for vitD3 deficiency and insufficiency.